← Back to ResearchRetatrutide LY3437943 triple agonist research: laboratory vial in dark cinematic setting

Retatrutide Research Guide: The Triple Agonist That Changed GLP-1 Science

Retatrutide available for research: View Retatrutide 5mg at UNIK LAB → — supplied as lyophilised peptide for in vitro and preclinical research use only.

At 48 weeks, the highest-dose cohort in Eli Lilly's Phase 2 trial lost 24.2% of their body weight. That's not a rounding error — it's a number that rewrote what researchers considered possible for a pharmacological intervention in obesity models.

Retatrutide (LY3437943) isn't just another incretin-based compound. It's the first triple-receptor agonist to complete Phase 2 clinical trials, hitting three distinct hormonal targets simultaneously in a way no approved drug currently does. The mechanism is genuinely different from tirzepatide. The data, when you actually read the NEJM paper, is striking.

Contents

  1. What Is Retatrutide? (LY3437943)
  2. The Triple Agonist Mechanism: Why 3 > 2
  3. Phase 2 Clinical Data: What the Numbers Actually Show
  4. Retatrutide vs Tirzepatide vs Semaglutide vs Liraglutide
  5. Pharmacokinetics: Half-Life and Dosing in Research
  6. Reconstitution Protocol for Research Studies
  7. Research Findings Beyond Weight: Liver, Cardio, Glucose
  8. Current Regulatory Status
  9. Quality Considerations for Research Sourcing
  10. FAQ

What Is Retatrutide? (LY3437943)

Retatrutide is a synthetic 39-amino acid peptide engineered by Eli Lilly as a triple agonist at three hormone receptors central to metabolic regulation: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its internal Eli Lilly compound code is LY3437943.

Core identifiers:

  • CAS Number: 2381089-83-2
  • Molecular Formula: C₂₂₁H₃₄₃N₄₇O₆₇
  • Molecular Weight: ~4,732 g/mol
  • Structure: 39 modified amino acids with a C20 dicarboxylic fatty acid side chain
  • Half-life: ~6 days (enabling once-weekly subcutaneous dosing in clinical research)

The fatty acid conjugation follows the same engineering logic that made semaglutide's half-life possible — albumin binding via the fatty acid chain dramatically slows renal clearance and extends bioavailability. Where semaglutide uses a C18 fatty diacid chain, retatrutide employs a C20 dicarboxylic variant, contributing to its slightly longer half-life.

What distinguishes retatrutide at the structural level is the balance of receptor activation. Unlike dual agonists that tilt heavily toward one receptor class, Coskun et al. (2022, Cell Metabolism, PMID 35985340) demonstrated in preclinical characterization that LY3437943 produces meaningful agonism across all three receptor types, with glucagon receptor activation more balanced relative to incretin activity than any prior triple agonist candidates.

The compound is not approved by any regulatory authority — the EMA, FDA, Health Canada, or equivalent — as of April 2026. Research use is strictly in vitro and preclinical.

The Triple Agonist Mechanism: Why 3 > 2

A Brief Timeline: From GLP-1 to Triple Agonism (2005–2026)

Understanding why the triple agonist approach took this long requires understanding the sequence of scientific revisions that made it possible.

2005: Exenatide (Byetta) becomes the first GLP-1 receptor agonist approved for clinical use. Pure GLP-1R agonism, twice daily dosing, modest efficacy (~3% weight loss). The proof-of-concept for incretin-based therapy.

2010: Liraglutide (Victoza) approved — once-daily, longer half-life via fatty acid conjugation, modestly better efficacy. The lipidation strategy opens the door to longer-acting compounds.

2017:Semaglutide Phase 3 data published (SUSTAIN programme). C18 fatty diacid chain achieves ~7-day half-life, once-weekly dosing, −14.9% body weight in obesity. The field's ceiling seemed to be around 15% weight loss for GLP-1R monoagonism.

2018–2020: Dual agonist development accelerates. The conceptual shift: what if adding GIPR agonism — previously assumed to be pro-lipogenic — was actually beneficial? Tirzepatide (LY3298176) Phase 1/2 data starts arriving. The hypothesis that GIP and GLP-1 receptors are synergistic, rather than redundant, gains experimental support.

2021:Tirzepatide Phase 3 (SURPASS programme) data shows −22.5% body weight at 72 weeks. The ceiling is not 15%. Dual agonism breaks through a barrier that monoagonism couldn't.

2022: Coskun T et al. publish the preclinical characterization of LY3437943 (retatrutide) in Cell Metabolism (PMID 35985340). In diet-induced obese mice, LY3437943 produced greater reductions in body weight, liver fat, and hepatic lipid content than either a GLP-1R/GIPR dual agonist or a GLP-1R/GCGR dual agonist at comparable doses.

2023: Jastreboff AM et al. (NEJM) and Rosenstock J et al. (Lancet) publish Phase 2 data. At 48 weeks, −24.2% weight reduction. The GLP-1 class ceiling rises again.

2024–2026: Phase 3 TRIUMPH programme ongoing. Retatrutide is the leading triple agonist candidate globally.

Each receptor brings something the others can't.

GLP-1R agonism slows gastric emptying, suppresses glucagon in a glucose-dependent manner, and promotes satiety centrally via hypothalamic and brainstem circuits.

GIPR agonismwas, for a long time, considered counterproductive. Tirzepatide's clinical data forced a revision of that assumption. GIPR agonism appears to enhance insulin sensitivity in adipose tissue, potentiate the GLP-1R signal, and may directly reduce food intake through CNS pathways distinct from GLP-1R. The synergy is real and wasn't fully predicted by preclinical models.

GCGR agonism is where retatrutide diverges from every other approved compound. Glucagon historically meant hyperglycaemia — the counter-regulatory hormone that raises blood glucose. The answer lies in the liver and in energy expenditure. GCGR agonism drives hepatic fat oxidation. In the context of simultaneous GLP-1R and GIPR activation, GCGR agonism adds a distinct thermogenic and lipolytic signal that neither incretin receptor can provide.

One critical finding from the preclinical work: GCGR activation in the presence of GLP-1R agonism appears to preserve glycaemic control that GCGR agonism alone would disrupt. The GLP-1R component provides sufficient insulin secretion stimulation and glucagon suppression to counterbalance the GCGR-mediated fasting gluconeogenesis. In isolation, a glucagon receptor agonist would cause hyperglycaemia. In the context of the triple agonist, that signal is metabolically redirected toward hepatic fat oxidation and energy expenditure without the glycaemic penalty.

Phase 2 Clinical Data: What the Numbers Actually Show

The definitive Phase 2 publication is:

Jastreboff AM et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 389(6):514–526. PMID: 37366315.

This was a randomised, double-blind, placebo-controlled trial. 338 participants without type 2 diabetes, BMI ≥27 kg/m². Five arms: placebo, 1 mg, 4 mg, 8 mg, and 12 mg retatrutide administered once weekly by subcutaneous injection over 48 weeks.

Weight reduction at 48 weeks, by dose:

DoseMean % body weight changePlacebo-adjusted
Placebo−2.1%—
1 mg−7.9%−5.8%
4 mg−17.3%−15.2%
8 mg−22.8%−20.7%
12 mg−24.2%−22.1%

At 12 mg, 26% of participants achieved ≥30% body weight reduction by 48 weeks — a threshold that had never been reached in a Phase 2 pharmacological trial for obesity prior to this study. The curve at 48 weeks had not plateaued in the 8 mg and 12 mg cohorts.

The type 2 diabetes Phase 2 data comes from:

Rosenstock J et al. (2023). “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo-controlled and active comparator phase 2 trial.” The Lancet, 402(10401):529–544. PMID: 37385280.

Key outcomes (12 mg dose vs dulaglutide 1.5 mg, 36 weeks in T2D):

  • HbA1c reduction: −2.20% vs −1.30% for dulaglutide
  • Body weight reduction: −16.9% at 36 weeks
  • Fasting plasma glucose: −3.75 mmol/L vs −0.91 mmol/L for dulaglutide

Adverse events were consistent with the GLP-1 class: predominantly nausea (40.7% at 12 mg), diarrhoea, vomiting, and decreased appetite — all dose-dependent and of mild-to-moderate intensity. Heart rate increase of 3–5 bpm was observed at higher doses — consistent with glucagon receptor activity.

Retatrutide vs Tirzepatide vs Semaglutide vs Liraglutide: The Complete Research Comparison

Compiled from published Phase 2/3 trial data, EMA/FDA submissions, and peer-reviewed pharmacological characterisations.

↔ Scroll horizontally to view the full table on mobile.

ParameterRetatrutide (LY3437943)Tirzepatide (LY3298176)SemaglutideLiraglutide
CAS Number2381089-83-22023788-19-2910463-68-6204656-20-2
Molecular Weight~4,732 g/mol~4,813 g/mol~4,114 g/mol~3,751 g/mol
Receptors TargetedGLP-1R + GIPR + GCGRGLP-1R + GIPRGLP-1R onlyGLP-1R only
Half-Life~6 days~5 days~7 days (sc)~13 hours
Max % Weight Loss (Phase 2/3)−24.2% (Phase 2, 48 wk)−22.5% (Phase 3, 72 wk)−14.9% (Phase 3, 68 wk)−8.0% (Phase 3, 56 wk)
Amino Acid Length39 aa (modified)39 aa (GIP-GLP-1 chimera)31 aa (GLP-1 analogue)31 aa (GLP-1 analogue)
Clinical Stage (2026)Phase 3 (TRIUMPH programme)Approved (FDA 2022 T2D; 2023 obesity)Approved (FDA/EMA — T2D, obesity, CV risk)Approved (FDA/EMA — T2D, obesity)
EMA/FDA ApprovalNone — research onlyFDA approved; EMA approvedFDA approved; EMA approvedFDA approved; EMA approved
Research AdvantagesStrongest weight loss signal in published trials; unique GCGR axis for hepatic fat studies; Phase 3 data incomingExtensive Phase 3 dataset; well-characterised GIP synergy mechanism; approved comparator for studiesBroadest evidence base; cardiovascular outcomes data (SUSTAIN-6); oral formulation availableDaily dosing for fine-grained kinetic studies; longest track record in research
Research LimitationsNo Phase 3 data yet; cardiovascular outcomes trial pending; regulatory status = research use onlyNo GCGR component; lower max weight loss than retatrutideNo GIPR or GCGR component; lower efficacy ceilingDaily injection; lowest efficacy in class; shortest half-life

Note: Weight loss figures from highest-dose arms in pivotal trials. Retatrutide comparison is Phase 2, not Phase 3. All percentages represent mean change from baseline.

Pharmacokinetics: Half-Life and Dosing in Research

Retatrutide's ~6-day terminal half-life places it between tirzepatide (~5 days) and semaglutide (~7 days) — all three are compatible with weekly subcutaneous dosing intervals.

The half-life is achieved via albumin-binding: the C20 dicarboxylic fatty acid chain at a specific lysine residue creates non-covalent binding to serum albumin, dramatically slowing renal filtration. The longer chain (C20 vs semaglutide's C18) contributes marginally to the half-life difference.

Dose escalation in Phase 2: Starting at 2 mg/week, escalating to maintenance dose over 20 weeks. Maximum studied dose: 12 mg/week.

For in vitro research, the compound is typically used in nanomolar concentrations to characterise receptor binding kinetics and downstream signalling. GIPR and GLP-1R activation can be measured via cAMP accumulation assays (HTRF or FRET-based formats). GCGR activation in hepatocyte cell lines is assessed via glycogenolysis or gluconeogenesis pathway markers.

Steady-state considerations: With a 6-day half-life and weekly dosing, steady state is reached after approximately 4–5 doses. Trough concentrations at steady state are ~50–60% of peak — a relatively flat pharmacokinetic profile that avoids pronounced peak/trough variability.

For general reconstitution and handling best practices, the UNIK LAB reconstitution guide covers sterile technique, solvent choice, and storage protocols applicable to retatrutide.

Reconstitution Protocol for Research Studies

Retatrutide triple agonist molecular structure: GLP-1R, GIPR, GCGR receptor pathways visualised

Retatrutide from UNIK LAB is supplied as lyophilised (freeze-dried) powder, typically 5 mg vials.

Recommended reconstitution for in vitro research:

  1. Solvent: Sterile water for injection or bacteriostatic water (0.9% benzyl alcohol). For cell culture, sterile PBS or saline avoids potential cytotoxicity from benzyl alcohol.
  2. Volume calculation: For a 1 mg/mL stock, add 5 mL solvent to a 5 mg vial. For 0.5 mg/mL: add 10 mL.
  3. Technique: Add solvent slowly along the vial wall — do not inject directly onto the powder cake. Do not vortex. Gentle swirling achieves dissolution in 30–60 seconds.
  4. pH note: Soluble at physiological pH. Avoid pH <4 or >8.
  5. Storage post-reconstitution:
    • Bacteriostatic water: 2–8°C, up to 28 days
    • Sterile water: −20°C, use within 7 days; avoid repeated freeze-thaw cycles
    • Aliquot into single-use volumes before freezing
  6. Stability check: Any visible cloudiness, colour change, or precipitate after reconstitution indicates degradation. Discard.
Research Note:Retatrutide's fatty acid chain is highly hydrophobic. In aqueous solution at physiological pH, it is monomeric and soluble at research-relevant concentrations (0.1–1 mg/mL). At concentrations above 5 mg/mL or under acidic conditions, aggregation is possible. UV spectroscopy at 280 nm can confirm absence of aggregates before use.

For COA verification, the UNIK LAB COA reading guide covers interpretation of analytical data specific to long-chain acylated peptides like retatrutide.

Disclaimer: All reconstitution information is provided for in vitro and preclinical research use only. Not intended for human administration.

Research Findings Beyond Weight: Liver, Cardio, Glucose

Hepatic Research: MASH and Liver Fat

The glucagon receptor component is directly relevant to hepatic lipid metabolism. Glucagon drives hepatic fatty acid oxidation and reduces hepatic lipogenesis — a pathway distinctly underserved by GLP-1 monoagonists. Sanyal AJ et al. (2024) examined liver outcomes in metabolic-associated steatohepatitis (MASH) models. The GCGR component of retatrutide provides a hepatic signal absent from tirzepatide, making it particularly relevant for hepatic steatosis and MASH progression research.

For comparison with other metabolic peptides in longevity and liver health contexts, the UNIK LAB best longevity peptides 2026 guide covers compounds with overlapping hepatic research applications.

Growth Hormone Axis Interactions

Glucagon receptor agonism stimulates GH secretion from the pituitary — a glucagon stimulation test has historically been used as a clinical probe for GH reserve. Researchers working at the intersection of metabolic biology and the GH/IGF-1 axis should note this interaction when designing experiments. The UNIK LAB Ipamorelin + CJC-1295 research guide covers GH secretagogue mechanisms relevant if your research involves metabolic-neuroendocrine interactions.

Cardiovascular Signal

The Rosenstock et al. Lancet data (PMID 37385280) in T2D subjects showed −5.3 mmHg reduction in systolic blood pressure at 12 mg vs −0.6 mmHg placebo — exceeding what GLP-1 monoagonism would predict at equivalent weight reduction. Heart rate increase of 3–5 bpm at 12 mg reflects GCGR-mediated cardiac expression. Cardiovascular outcomes data is not yet available — the relevant Phase 3 outcomes trial had not reported as of April 2026.

Glucose Metabolism

HbA1c reduction of −2.20% at 12 mg (vs −1.30% for dulaglutide at 36 weeks) and fasting glucose reduction of −3.75 mmol/L substantially exceed what GLP-1 monoagonism alone explains, implicating GCGR-mediated reduction in hepatic glucose output. In cell-based β-cell biology research, retatrutide is a useful tool compound for dissecting GLP-1R and GIPR co-stimulation signalling via the adenylate cyclase/cAMP pathway.

Adverse Events Across Phase 2 Studies

Gastrointestinal effects (dominant safety signal):

  • Nausea: 40.7% at 12 mg; transient, peaking during dose escalation
  • Vomiting: 24.3% at 12 mg; <10% in lower-dose arms
  • Diarrhoea: 21.7% at 12 mg; constipation less common than semaglutide comparator arms
  • Decreased appetite: 32.2% at 12 mg

Cardiovascular parameters:

  • Heart rate: +3–5 bpm at 12 mg (GCGR activity). Not clinically significant in Phase 2.
  • Blood pressure: −5.3 mmHg systolic at 12 mg (T2D trial)

No pancreatitis cases in Phase 2. Gallbladder events: 3.7% cholelithiasis (all groups) vs 1.1% placebo — consistent with rapid weight loss, not specific to retatrutide. No unexpected adverse findings beyond the known GLP-1 class profile plus the anticipated GCGR-related heart rate effect.

Current Regulatory Status

As of April 2026, retatrutide has no marketing authorisation from any regulatory agency.

Phase 3 programme (TRIUMPH):

  • TRIUMPH-1/2: Obesity (BMI ≥30, or ≥27 with comorbidity) — comparing retatrutide vs placebo over 72 weeks
  • TRIUMPH-3: Type 2 diabetes — head-to-head vs tirzepatide
  • Cardiovascular outcomes trial: Anticipated through the Phase 3 programme period

Phase 3 results are anticipated between late 2026 and 2027 for the obesity indication. Regulatory submission to FDA/EMA is contingent on Phase 3 outcomes. Retatrutide is therefore currently available only as a research compound — not for human administration, clinical use, or veterinary prescription.

Quality Considerations for Research Sourcing

The quality requirements for a long-chain acylated peptide like retatrutide are more demanding than for simpler research peptides. The C20 fatty acid conjugation step introduces complexity — both in synthesis and in quality control.

What a research-grade COA should confirm:

  • HPLC purity: ≥99% by reverse-phase HPLC. C18 column analysis with UV detection at 220 nm.
  • Mass spectrometry confirmation: ESI-MS or MALDI-TOF confirming the correct molecular ion at ~4,732 g/mol. Rules out truncated sequences or acylation failures.
  • Endotoxin testing: LAL assay, <1 EU/mg. Critical for cell culture applications.
  • Sterility certificate: For in vitro use.
  • Counter-ion specification: Acetate salt preferred over TFA for in vitro work — TFA residues are cytotoxic at cell-based assay concentrations.

The UNIK LAB guide to reading peptide COAs covers how to interpret each of these analytical parameters.

UNIK LAB retatrutide is tested to ≥99% HPLC purity with full mass spec confirmation and COA on every batch. Available in 5 mg vials as lyophilised acetate salt.

Research-Grade Retatrutide from UNIK LAB
Supplied as lyophilised acetate salt, ≥99% HPLC purity, full COA with mass spec confirmation. For in vitro and preclinical research use only.
View Retatrutide 5mg →

Research FAQ

What is retatrutide's chemical name and Eli Lilly code?

Retatrutide is the INN (International Non-proprietary Name). Eli Lilly's internal designation is LY3437943. CAS number: 2381089-83-2. Molecular formula: C₂₂₁H₃₄₃N₄₇O₆₇. Molecular weight: approximately 4,732 g/mol. The structure consists of 39 modified amino acids with a C20 dicarboxylic fatty acid side chain attached via a linker to a specific lysine residue.

How does retatrutide differ from tirzepatide mechanistically?

Tirzepatide (LY3298176, Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist adding glucagon receptor (GCGR) activation to the GIP/GLP-1 combination. The glucagon receptor component drives hepatic fatty acid oxidation, a pathway neither tirzepatide nor semaglutide activates. In Phase 2, retatrutide produced −24.2% weight reduction at 48 weeks vs tirzepatide's −22.5% at 72 weeks in Phase 3 — though these are not directly comparable given different populations, durations, and trial phases.

What did Phase 2 trials actually show for retatrutide's weight loss?

The Jastreboff et al. (2023, NEJM, PMID 37366315) Phase 2 obesity trial showed mean body weight reduction of −24.2% at 48 weeks in the 12 mg/week arm vs −2.1% for placebo. In the 8 mg arm: −22.8%. Notably, weight loss curves had not plateaued at 48 weeks in the highest dose groups. 26% of participants in the 12 mg arm achieved ≥30% body weight reduction.

Is retatrutide approved for human use?

No. As of April 2026, retatrutide holds no marketing authorisation from the FDA, EMA, Health Canada, TGA, or any equivalent regulatory authority. It is in Phase 3 clinical trials (the TRIUMPH programme) for obesity and type 2 diabetes. UNIK LAB supplies retatrutide strictly for in vitro research and preclinical study use only.

How should retatrutide be reconstituted for in vitro research?

Reconstitute with sterile water for injection or bacteriostatic water, adding solvent slowly along the vial wall and swirling gently. For cell culture applications, sterile PBS or saline is preferable. A standard 1 mg/mL stock is prepared by adding 5 mL solvent to a 5 mg vial. Store at 2–8°C (bacteriostatic water: up to 28 days; sterile water: use within 7 days).

What are the main adverse events observed in retatrutide Phase 2 trials?

The adverse event profile mirrors the GLP-1 class: nausea (40.7% at 12 mg), diarrhoea, vomiting, constipation, and decreased appetite — predominantly mild-to-moderate and dose-dependent. A heart rate increase of 3–5 bpm was observed at higher doses (GCGR activity). No serious cardiovascular events were attributed to retatrutide in Phase 2.

What is the half-life of retatrutide and how does this affect experimental design?

Retatrutide has a terminal half-life of approximately 6 days, enabling once-weekly subcutaneous dosing. In vitro, it is functionally stable with no rapid degradation during standard incubation periods (24–72 hours). Steady state is reached after approximately 4–5 weekly doses in in vivo models.

Related Research

Research Disclaimer: All content on this page is provided for informational and educational purposes only. Retatrutide is not approved for human use by any regulatory authority. UNIK LAB supplies this compound exclusively for in vitro research and preclinical laboratory use. This content does not constitute medical advice and should not be interpreted as a recommendation for human administration.